Welcome to our dedicated page for Structure Therapeutics SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Structure Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Structure Therapeutics's regulatory disclosures and financial reporting.
Structure Therapeutics Inc. (GPCR) reported positive clinical updates for its two lead oral obesity candidates, the amylin agonist ACCG‑2671 and the GLP‑1 receptor agonist aleniglipron. ACCG‑2671’s Phase 1/2a single‑ascending‑dose study in 31 healthy adults showed a ~6‑day half‑life, dose‑proportional exposure, and no serious adverse events or drug‑induced liver injury.
A single 10 mg dose of ACCG‑2671 produced a 3.3% mean body‑weight reduction at Day 24 and about a 60% drop in CTX‑1, supporting target engagement; gastrointestinal events appeared at 5–10 mg and are guiding titration in an ongoing 12‑week multiple‑dose trial, with topline data expected in the first half of 2027.
Aleniglipron’s 72‑week ACCESS open‑label extension showed continued weight loss, with participants from the 120 mg arm titrated to 180 mg achieving 16.2% mean weight loss, and more than one‑third of those in the 90 mg and 120 mg cohorts exceeding 20% body‑weight reduction, while fewer than 5% discontinued due to adverse events. A “start‑low, go‑slow” titration from 2.5 mg improved gastrointestinal tolerability. Aleniglipron is now in two global Phase 3 ACCOMPLISH trials enrolling about 3,600 and 1,100 patients, with topline data expected in the second half of 2028.
Structure Therapeutics Inc. (GPCR) reported that its Chief Scientific Officer, Xichen Lin, exercised options for 17,817 Ordinary Shares at an exercise price of $0.34 per share on September 1, 2026, leaving 125,081 Ordinary Shares subject to the option.
The 17,817 Ordinary Shares were converted into 5,939 American Depositary Shares (ADSs), each ADS representing three Ordinary Shares, and all 5,939 ADSs were sold in multiple transactions at weighted average prices of $45.8642 and $47.2030 per ADS. The ADS sales were made under a Rule 10b5-1 trading plan entered into on March 26, 2026.
Structure Therapeutics Inc. (GPCR) reported insider activity by Chief Scientific Officer Xichen Lin involving option exercises, ADS conversions, and sales on 2026-08-18. Lin exercised options for 11,817 Ordinary Shares at $0.34 per share, which were converted into 3,939 American Depositary Shares (ADSs). All 3,939 ADSs were then sold in three tranches at weighted average prices of $53.133, $54.197, and $55.05 per ADS under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following the partial exercise, 142,898 Ordinary Shares remain subject to the option.
Structure Therapeutics Chief Commercial Officer John Joseph Berrios received equity awards on 2026-08-06. He was granted 174,612 share options with an exercise price of 17.54 per Ordinary Share, expiring 2036-08-05, plus 140,766 restricted share units. The RSUs vest one-fourth annually from August 6, 2026, and the options vest one-fourth on that date and in thirty-six equal monthly installments thereafter, in each case subject to his continued service. Each Ordinary Share may be represented by an ADS, with each ADS representing three Ordinary Shares.
Structure Therapeutics Inc. submitted a Form 3 for insider John Joseph Berrios, who serves as Chief Commercial Officer.
The report shows no buy, sell, or other equity transactions, no derivative transactions, and no holdings reported for him as of this initial statement.
Structure Therapeutics Inc., a clinical-stage biopharma focused on oral GPCR-targeted drugs for obesity and related diseases, reported a net loss of $106.2 million for Q2 2026 and $182.1 million for the first half, driven mainly by higher research and development spending.
R&D expenses were $100.1 million in Q2 and $166.6 million year-to-date, reflecting Phase 2 and Phase 3 work on oral GLP‑1 agonist aleniglipron and amylin programs. General and administrative costs were $18.6 million in Q2, while interest and other income contributed $26.3 million in H1.
As of June 30 2026, cash, cash equivalents and short-term investments totaled $1,342.7 million, with an accumulated deficit of $652.4 million. The company states this liquidity should fund projected operations and key clinical milestones, including the Phase 3 ACCOMPLISH program for aleniglipron, through the end of 2028.
Structure Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026 and highlighted advances in its obesity-focused pipeline. First patients were dosed in the Phase 3 ACCOMPLISH program evaluating aleniglipron, a once-daily oral GLP-1 receptor agonist, for chronic weight management. Phase 2b ACCESS data, published in Nature Medicine and presented at the ADA Scientific Sessions, showed dose-dependent, clinically meaningful and statistically significant body-weight reductions, with weight loss up to 16.2% at 44 weeks in an open-label extension and an overall discontinuation rate of 10.4%.
The company is also progressing ACCG-2671, an oral dual amylin and calcitonin receptor agonist, with Phase 1 single ascending dose data and a multiple ascending dose trial planned for the third quarter of 2026, and additional aleniglipron and GLP-1/amylin combination data in the second half of 2026. Cash, cash equivalents and short-term investments were $1.3 billion as of June 30, 2026, which Structure Therapeutics expects will fund projected operations and key clinical milestones through the end of 2028. In the second quarter of 2026, research and development expenses were $100.1 million, general and administrative expenses were $18.6 million, and net loss totaled $106.2 million.
FMR LLC filed an amended ownership report for Structure Therapeutics Inc., disclosing beneficial ownership of 28,197,369 shares of common stock, representing 13.2% of the class. FMR LLC reports sole voting power over 28,197,321 shares and sole dispositive power over 28,197,369 shares, with no shared voting or dispositive power.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 28,197,369 shares, but no voting power. The filing notes that one or more other persons have rights to receive dividends or sale proceeds from these shares, although no such person holds more than five percent of the common stock. The report is signed on behalf of FMR LLC and Abigail P. Johnson under powers of attorney.
Structure Therapeutics chief scientific officer Xichen Lin exercised options for 11,817 Ordinary Shares at $0.34 per share on August 4, 2026, converted them into 3,939 American Depositary Shares, and sold all ADS in two trades at weighted average prices of $49.2857 and $50.0290 pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026. Following this partial exercise, a share option over 154,715 Ordinary Shares remains outstanding.
FMR LLC, a more than 10% owner of Structure Therapeutics Inc., reported indirect sales totaling 17,452 American Depositary Shares on July 22, 2026, in open-market or private transactions at a weighted average $50.07 per ADS via F-Prime funds. Each ADS represents three ordinary shares. FMR and related persons continue to report large indirect holdings, including positions tied to 4,546,674 ordinary shares, and disclaim beneficial ownership of the reported securities.